Zhu, Li <br/><br/>
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Jul 2015 
 - 3816-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1098-6596 
<br/><br/><label>Standard No.: </label>10.1128/AAC.04914-14  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Anti-HIV Agents--adverse effects<br/>Atazanavir Sulfate--adverse effects<br/>Cross-Over Studies<br/>Drug Interactions<br/>Drug Therapy, Combination<br/>Female<br/>HIV Envelope Protein gp120--metabolism<br/>HIV Fusion Inhibitors--adverse effects<br/>HIV-1--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Organophosphates--therapeutic use<br/>Piperazines--adverse effects<br/>Ritonavir--adverse effects<br/>Triazoles--adverse effects<br/>Young Adult